HCW Biologics (HCWB) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on proprietary immunotherapies for chronic inflammation and age-related diseases.

• Lead programs target cancer, autoimmune, and quality-of-life conditions using TOBI and TRBC platforms.

• Business strategy includes in-house clinical trials for select candidates and out-licensing non-core assets.

• Experienced management team with prior success in immunotherapeutics and significant industry transactions.

Financial performance and metrics

• Reported net losses of $25.0 million in 2023 and $30.3 million in 2024, with cumulative net losses of $98.1 million since inception.

• Cash and cash equivalents as of December 31, 2024, were $4.7 million, raising substantial doubt about ability to continue as a going concern.

• No commercial revenues to date; revenue has been limited to licensing and supply agreements.

• Reverse stock split (1-for-40) effective April 11, 2025, to regain Nasdaq compliance.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.4 million (if fully subscribed), with no minimum offering amount.

• Proceeds intended for preclinical and clinical development (notably HCW9302), R&D, business development, patent expansion, pivotal studies, and general corporate purposes.

• Management has broad discretion over allocation of proceeds.